Citizens Maintains Market Outperform on Precigen, Raises Price Target to $11

Benzinga Newsdesk www.benzinga.com Positive 89.3%

Neg 0% Neu 0% Pos 89.3%

Citizens analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform and raises the price target from $9 to $11.